Maxim Group set a $4.00 price target on AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also issued reports on AEZS. Zacks Investment Research raised AEterna Zentaris from a sell rating to a hold rating in a report on Tuesday, July 11th. HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the company a buy rating in a report on Wednesday, July 5th.

AEterna Zentaris (NASDAQ AEZS) opened at 2.05 on Friday. The firm has a 50 day moving average price of $1.59 and a 200-day moving average price of $2.07. The firm’s market capitalization is $29.38 million. AEterna Zentaris has a 12 month low of $0.78 and a 12 month high of $5.59.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.05. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.22 million. AEterna Zentaris had a negative net margin of 1,945.78% and a negative return on equity of 502.76%. The firm’s quarterly revenue was up 153.1% on a year-over-year basis. On average, equities analysts forecast that AEterna Zentaris will post ($1.29) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Stock Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related stocks with our FREE daily email newsletter.